“AKINETON” RETUNRS TO THE RUSSIAN MARKET AT A REDUCED PRICE

24-04-2019 | 16:03

The Antimonopoly Service approved the maximum ex-works prices for the medicine

 

The story with “Akineton” (bipereden) disappearing from the Russian market, that caused a stir, has reached its logical end. “Desma GmbH” finally met the norms of the law1 and reregistered the medicine price, reduced to the minimum price level in the reference countries. Now the manufacturer’s price for Russian patients  on “Akineton” solution 5 mg/ml, 1 ml, 5 ampoules, no more than 167.98 RUB (against earlier registered 611.83 RUB), and for “Akineton” tablets 2 mg, 20 pieces, blister 5 pieces – 223.46 RUB (used to be 423.41 RUB).

 

Earlier FAS abolished the decisions of the Federal Tariff Services made in 2010 on approving the maximum ex-works prices for the medicine manufactured by “Desma GmbH” (Germany) because at the time of registration the company gave incorrect data: there was no information about medicine prices in the reference countries. The ex-works prices in those countries were considerably low the prices applied for registration in the Russian Federation. It means that prices registered in Russia were unreasonably high.

 

FAS requested “Desma GmbH” to reduce prices. Instead of reducing many-fold overrated prices and ensuring uninterrupted access of patients to the medicine, the company preferred judicial proceedings. Courts of four instances, including the Supreme Court of the Russian Federation, confirmed legitimacy and reasonableness of FAS actions.

 

Deputy Head of FAS Andrey Tsarikovskiy said: “The situation with “Akineton” clearly shows that the recent hysteria blown out of proportion by market participants in mass media up around reregistering medicine prices was groundless. For example, the company agreed to reduce prices to the allowed level confirms not only the manufacturer’s interest in the Russian market but also the fact that there is room for companies to reduce prices. Once again, I’d like to repeat that our patients must be able to get medicine at the prices not more expensive than medicine prices in European countries”.

 

1 No. 865 Decree of the Government of the Russian Federation (version of 08.10.2018) "On state regulation of prices for the medicine included in the list of vital and essential ones” of 29.10.2010



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide